SCHEMBL5468602

SCHEMBL5468602

CC(C)(C)OC(=O)N1C(=O)C(=Cc2c[nH]c3ccccc23)c2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NTRK1 P04629 4/20 0.46
PRKD3 O94806 2/20 0.46
ABL1 P00519 2/20 0.46
RET P07949 2/20 0.46
PDGFRB P09619 2/20 0.46
LTK P29376 2/20 0.46
KDR P35968 2/20 0.46
FLT3 P36888 2/20 0.46
CSNK1A1 P48729 2/20 0.46
CDK7 P50613 2/20 0.46
MAP2K1 Q02750 2/20 0.46
MST1R Q04912 2/20 0.46
NTRK3 Q16288 2/20 0.46
NTRK2 Q16620 2/20 0.46
AURKB Q96GD4 2/20 0.46
CLK4 Q9HAZ1 2/20 0.46
ALK Q9UM73 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14448846 1.00 MAPT (0.47) MAPTMEN1KMT2ANTRK1PRKD3
SCHEMBL5468598 1.00 MAPT (0.47) MAPTMEN1KMT2ANTRK1PRKD3
SCHEMBL7694409 0.83 NTRK1 (0.52) MAPTMEN1KMT2ANTRK1PRKD3
SCHEMBL699152 0.79 APP (0.57) MAPTALDH1A1APPSNCACDK1
SCHEMBL5478682 0.77 NTRK1 (0.55) MAPTMEN1KMT2ANTRK1PRKD3
SCHEMBL7783118 0.77 NTRK1 (0.55) MAPTMEN1KMT2ANTRK1PRKD3
SCHEMBL5478687 0.77 NTRK1 (0.55) MAPTMEN1KMT2ANTRK1PRKD3
SCHEMBL14448859 0.77 NTRK1 (0.55) MAPTMEN1KMT2ANTRK1PRKD3
SCHEMBL21342890 0.76 KMT2A (0.45) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL28266654 0.74 BCHE (0.47) MAPTALDH1A1KDM4EAPPSNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 MAPT 1309/4885MEN1 1603/4885KMT2A 1891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.